Company News

Share this article:

Sanofi-Aventis will acquire California-based BiPar Sciences for up to $500 million. BiPar Sciences is a pharma focused on a novel cancer treatment, known as BSI-201. The acquisition is the third this month for Sanofi – the company purchased Medley, a Brazillian generics manufacturer, and Laboratorious Kendrick, a Mexican generic company.

 

Johnson & Johnson announced that it will shift its wellness and disease-prevention business under the consumer business umbrella. J&J had initially planned to develop a separate wellness and disease-prevention business, with the acquisition of Michigan-based HealthMedia, according to a Wall Street Journal report.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions